News and Comments

Onyx (ONXX) Was Right All Along

  Monday, July 26, 2010

In October 2009, Onyx (ONXX) paid $276 million up front to acquire the privately held Proteolix to get to its multiple myeloma drug carfilzomib. It promised $535 million in future payments largely contingent on carfilzomib's approval. As usual, investors did not like Onyx paying money, because investors do not like any company to pay money to develop or acquire state-of-the- art products. When somebody hates something he sees everything in it with pessimism. Onyx put its hands on carfilzomib, which looked very promising for multiple myeloma cases resistant to current treatments. The breakthrough multiple myeloma drugs Velcade (bortezomib) and Revlimid (lenolidamide) could not prevent the cancer from recurring and failed to work at all on a large percentage of recurrent cancer.  More...


Recent Postings


Archive


Tags

Prosensa (RNA) galapagos (GLPG) Array Pharmaceuticals (ARRY) Ariad (ARIA) Dynavax (DVAX) Anacor (ANAC) Agenus (AGEN) Telaprevir VANDA (VNDA) TOKAI (TKAOI) Incyte (INCY) KITE (KITE) AERIE PHARMACEUTICALS Auspex (ASPX) OncoCyte (OCX) Bristol-Myers Squibb (BMY) Ocular Therapeutix (OCUL) Inovio (INO) ACADIA (ACAD) Agenus (AGEN Amgen (AMGN) Vertex (VRTX) IDERA (IDRA) KERYX (KERX) ISIS (ISIS) AstraZeneca (AZN) ARGOS (ARGS) OSI (OSIP) GlaxoSmithKline (GSK) GUARDIAN HEALTH Intercept (ICPT) Sanofi-Aventis (SAN) Exelixis (EXEL) Human Longevity (HLI) Xoma (XOMA) Ionis (IONS) Tysabri Galena (GALE) Merck (MRK) Sanofi (SNA) Vitae Pharmaceuticals (VTAE) NOVOCURE (NVCR) BIOMARIN (BMRN) ZALTRAP™ SERES THERAPEUTICS (MCRB) Advaxis (ADXS) AGOS (ARGS) Roche (ROCHE) ABBVIE (ABBV) Genentech Trastuzumab-DM1 Herceptin Benlysta (belimumab) ImmunoGen (IMGN) JOUNCE THERAPEUTICS (JNCE) ARCA (ABIO) NANTKWEST (NK) Illumina (ILMN) Ziofpharm (ZIOP) Revlimid (lenolidamide) Roche (RHHBY) Human Genome Sciences (HGSI) PTC Therapeutics (PTCT) LEXICON (LXRX) MODERNA Cytokinetics (CYTK) Sarepta (SRPT) Alnylam (ALNY) Intrexon (XON) Alder Biopharmaceuticals (ALDR) Adaptimmune (ADAP) JUNO (JUNO) Prolor Biotech (PBTH) SYNTA (SNTA) Rapamune CRISPR Therapeutics (CRSP) CompuGen (CGEN) Editas (EDIT) PORTOLA (PTLA) Endometrial Cancer Sequenom (SQNM) Pluristem (PSTI) Biogen Idec (BIIB) C4 Therapeutics Sanofi (SNY) Multiple Myeloma Jazz Pharmaceuticals (JAZZ) Zerenex Intermune (ITMN) RenenxBio (RGNX) Theravance Bio Pharma (TBPH) Ridaforolimus Dendreon (DNDN) Regeneron (REGN) Aimmune Therapeutics (AIMT) Global Cell Therapeutics (GBT) Spike Therapeutics (ONCE) CEMPRA (CEMP) Anadys (ANDS) Abbott Laboratories (ABT) Theravance (THRX) Micromet (MITI) Gilead (GILD) Onyx (ONXX) NEKTAR (NKTR)) Bellicum (BLCM) Mirati Therapeutics (MRTX) INNOVIVA (INVA) Elan (ELN) Idenix (IDIX) REGULUS (RGLS) Seattle Genetics (SGEN) Biocryst (BCRX) Sangamo (SGMO) ADVENTRIX (ANX) SUNESIS PHARMACEUTICALS (SNSS) Velcade (bortezomib) HALOZYME (HALO) Valeant Pharmaceuticals International (VRX)